Selected Scientific Publications from the Morgan Welch Inflammatory Breast Cancer Program

Efficient synthesis of apricoxib, CS-706, a selective cyclooxygenase-2 inhibitor, and evaluation of inhibition of prostaglandin E2 production in inflammatory breast cancer cells.
Mandal PK, Freiter EM, Bagsby AL, Robertson FM, McMurray JS.
Bioorg Med Chem Lett. 2011 Oct 15;21(20):6071-3. Epub 2011 Aug 19.

Genomic and Proteomic Pathway Mapping 3 Reveals Signatures of Mesenchymal-Epithelial 4 Plasticity in Inflammatory Breast Cancer.
Fredika M. Robertson et al.
Breast Cancer - Recent Advances in Biology, Imaging and Therapeutics. Croatia, 2011

Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer.
Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA.
The Oncologist. In Press. 

MRI features of inflammatory breast cancer.
Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT..
AJR Am J Roentgenol. 2011 Oct;197(4):W769-76.

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer.
Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT.
Breast Cancer Res Treat. 2011 Feb;125(3):785-95. Epub 2010 Dec 9.

Identifying factors that impact survival among women with inflammatory breast cancer.
Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M.
Ann Oncol. 2011 Jul 15. 

Circulating tumor cells in metastatic Inflammatory Breast Cancer.
Mego M, De Giorgi U, Hsu L, Ueno NT, Valero V, Jackson S, Andreopoulou E, Kau SW, Reuben JM, Cristofanilli M. Ann Oncol 20(11):1824-8, 11/2009.

Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy.
Giordano A, Giuliano M, De Laurentiis M, Arpino G, Jackson S, Handy BC, Ueno NT, Andreopoulou E, Alvarez RH, Valero V, De Placido S, Hortobagyi GN, Reuben JM, Cristofanilli M. Ann Oncol 23(5):1144-50, 5/2012. e-Pub 9/2011. 

Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients.
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM.  Breast Cancer Res Treat 129(2):451-8, 9/2011. 

Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM.  Int J Cancer 130(4):808-16, 2/2012. e-Pub 4/2011. 

Characterization of metastatic breast cancer patients with non-detectable circulating tumor cells.
Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, Handy B, Ueno NT, Reuben JM, Cristofanilli M.  Int J Cancer 129(2):417-23, 7/2011. 

Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer.
De Giorgi U, Mego M, Scarpi E, Giuliano M, Giordano A, Reuben JM, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M.  Clin Breast Cancer 12(4):264-9, 8/2012. e-Pub 5/2012.  

Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. . Breast Cancer Res 13(3):R67, 2011. 

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM, Reuben JM, Cristofanilli M, Buchholz TA, Woodward WA.  Breast Cancer Res Treat.
e-Pub 5/2012. 

Stromal-derived factors that dictate organ-specific metastasis.
Eckhardt, B.L., Smith, T.L., Anderson, R.L., Arap, W. and Pasqualini, R. (2011). In: Cancer Metastasis: Biologic Basis and Therapeutics. Cambridge University Press.

Strategies to consider during the discovery and development of therapies for metastatic breast cancer.
Eckhardt, B.L., Francis, P.A., Parker, B.P., and Anderson, R.L. (2012). Nature Reviews Drug Discovery. 11(6):479-97.  

Metastasis in the Breast Mimicking Inflammatory Breast Cancer.
Alvarez RH, Gong Y, Ueno NT, Alizadeh PA, Hortobagyi GN, Valero V. J Clin Oncol. 2012. 

Inflammatory breast cancer: what we know and what we need to learn.
Ueno NT, Cristofanilli M. Inflammatory Breast Cancer: An Update. Springer; 2012.
Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, et al. Oncologist. 2012;17:891–9. 

FDG-PET/CT Compared with Conventional Imaging in the Detection of Distant Metastases of Primary Breast Cancer.
Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu T-K, Liu J, et al. Oncologist. 2011.

Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer.
Niikura N, Liu J, Costelloe CM, Palla SL, Madewell JE, Hayashi N, et al. Oncologist. 2011;16:772–82. 

Targeting EGFR in Triple Negative Breast Cancer.
Ueno NT, Zhang D.  J Cancer. 2011;2:324–8. 

Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
Zhang D, Tari AM, Akar U, Arun BK, LaFortune TA, Nieves-Alicea R, et al. Mol Cancer Ther. 2010;9:3090–9. 

ABC conceptual model of effective multidisciplinary cancer care (Jpn).
Ueno NT, Ito TD, Grigsby RK, Black MV, Apted J. Nature Reviews Clinical Oncology. 2010;7:544–7. 

Targeted therapy in inflammatory breast cancer.
Yamauchi H, Ueno NT. Cancer. 2010;116:2758–9. 

Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs.
Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A Jr, Ueno NT, Buchholz TA.
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1381-6. doi: 10.1016/j.ijrobp.2011.10.040. Epub 2012 Jan 26. 

Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome.
Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M.
Cancer. 2011 Dec 15;117(24):5476-84. doi: 10.1002/cncr.26179. Epub 2011 Jun 28. 

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment.
Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. Ann Oncol 22(3):515-23, 3/2011. e-Pub 7/2010. 

MRI features of inflammatory breast cancer.
Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell RK, Reed BJ, Yang WT. AJR Am J Roentgenol 197(4):W769-76, 10/2011. 

Pretreatment staging Positron Emission Tomography/Computed Tomography in patients with inflammatory breast cancer influences radiation treatment field designs.
Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Int J Radiat Oncol Biol Phys. e-Pub 1/2012. 

Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: Is there a reliable threshold for differentiating benign from malignant?
Carkaci S, Adrada BE, Rohren E, Wei W, Quraishi MA, Mawlawi O, Buchholz TA, Yang W. Acad Radiol. e-Pub 2/2012. 

Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy.
Scoggins ME, Stafford RJ, Yang WT. Breast Diseases: A Year Book Quarterly 23(3):235-237, 9/2012.